Article
Author(s):
Radhakrishnan Ramchandren, M.D., from the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, discusses the role of clinical trials in developing news drugs and standards of care for patients with lymphoma.
Radhakrishnan Ramchandren, M.D., from the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, discusses the role of clinical trials in developing news drugs and standards of care for patients with lymphoma.
In particular, Ramchandren acknowledged that the success from these trials should not be underestimated or underemphasized. In turn, this is why patients should be evaluated for clinical trials and discuss potential eligibility, especially given the landscape of lymphoma, he said.